A Phase III, randomized, two armed, parallel, double blind, active controlled, non-inferiority clinical trial to determine the non-inferior therapeutic efficacy and safety between Denosumab (60 mg, produced by AryoGen Pharmed) compared with Prolia (60 mg, Denosumab, the reference drug, produced by Amgen Company) in improvement of bone mineral densitometry (BMD) among osteoporotic postmenopausal women

Trial Profile

A Phase III, randomized, two armed, parallel, double blind, active controlled, non-inferiority clinical trial to determine the non-inferior therapeutic efficacy and safety between Denosumab (60 mg, produced by AryoGen Pharmed) compared with Prolia (60 mg, Denosumab, the reference drug, produced by Amgen Company) in improvement of bone mineral densitometry (BMD) among osteoporotic postmenopausal women

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Denosumab (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Sponsors AryoGen Pharmed
  • Most Recent Events

    • 19 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top